TY - JOUR
T1 - Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library
AU - Shepshelovich, Daniel
AU - McDonald, Kate
AU - Spreafico, Anna
AU - Razak, Albiruni R.A.
AU - Bedard, Philippe L.
AU - Siu, Lillian L.
AU - Minasian, Lori
AU - Hansen, Aaron R.
N1 - Publisher Copyright:
© AlphaMed Press 2019
PY - 2019/4
Y1 - 2019/4
N2 - The patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) complements capture of symptomatic adverse events (AEs) by clinicians. Previous trials have typically used a limited subset of relevant symptomatic AEs to reduce patient burden. We aimed to determine the feasibility of administering all 80 AEs included in the PRO-CTCAE library by approaching consecutive patients enrolled in a large academic phase I program at three points in time. Here, we report a preplanned analysis after enrolling the first 20 patients. All items were answered on 51 of 56 potential visits (adherence 91%). Three (5%) additional PRO-CTCAE assessments were partially completed, and two (4%) were missed because of conflicting appointments. No patient withdrew consent or chose not to complete the assessments once enrolled on study. Future trials of experimental drugs that incorporate the PRO-CTCAE should consider using this unselected approach to identify adverse events more completely.
AB - The patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) complements capture of symptomatic adverse events (AEs) by clinicians. Previous trials have typically used a limited subset of relevant symptomatic AEs to reduce patient burden. We aimed to determine the feasibility of administering all 80 AEs included in the PRO-CTCAE library by approaching consecutive patients enrolled in a large academic phase I program at three points in time. Here, we report a preplanned analysis after enrolling the first 20 patients. All items were answered on 51 of 56 potential visits (adherence 91%). Three (5%) additional PRO-CTCAE assessments were partially completed, and two (4%) were missed because of conflicting appointments. No patient withdrew consent or chose not to complete the assessments once enrolled on study. Future trials of experimental drugs that incorporate the PRO-CTCAE should consider using this unselected approach to identify adverse events more completely.
UR - http://www.scopus.com/inward/record.url?scp=85061316934&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2018-0332
DO - 10.1634/theoncologist.2018-0332
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30728278
AN - SCOPUS:85061316934
SN - 1083-7159
VL - 24
SP - e146-e148
JO - Oncologist
JF - Oncologist
IS - 4
ER -